Streetbeat News

Analyst Ratings

BWXT

Truist Securities analyst Michael Ciarmoli has reiterated a Buy rating on BWX Technologies, Inc. (BWXT), raising the price target to $83 from $77. Ciarmoli believes that BWXT's numerous revenue growth drivers, monopolistic market positions, and a resurgence in the commercial nuclear market will enable it to post best-in-class results among its peers over the next 12-36 months. The analyst also sees signs of microreactor adoption in the commercial market and anticipates that the high-margin medical rev growth acceleration will complement stability in the company's core naval defense market.

Portfolio Pulse from Nabaparna Bhattacharya

August 14, 2023 | 7:22 pm

TMUS

A significant investor has taken a bearish stance on T-Mobile US (NASDAQ:TMUS), with 88% of the spotted trades being bearish. The whales have been targeting a price range from $115.0 to $150.0 for T-Mobile US over the last 3 months. The current price of TMUS is $138.98, up 0.46%. RBC Capital, Morgan Stanley, and TD Cowen maintain their positive ratings on T-Mobile US, with price targets of $163, $179, and $210 respectively, while Benchmark downgraded its action to Buy with a price target of $200.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:16 pm

MMM

A significant bearish stance has been taken on 3M (NYSE:MMM) as evidenced by unusual options activity. The overall sentiment of these big-money traders is 100% bearish. The whales have been targeting a price range from $85.0 to $125.0 for 3M over the last 3 months. Currently, the price of MMM is down -1.13% at $103.37. Citigroup, Morgan Stanley, and RBC Capital have maintained their Neutral, Underweight, and Underperform ratings on 3M, respectively.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:16 pm

APA

In the last quarter, APA (NASDAQ:APA) received a mix of analyst ratings, with 4 bullish, 7 indifferent, and 4 bearish. The average 12-month price target for APA is $43.0, a decrease of 3.78% from the previous average of $44.69.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm

AZUL

In the last quarter, Azul (NYSE:AZUL) received 2 somewhat bullish and 4 indifferent analyst ratings. The average 12-month price target for Azul over the last 3 months is $13.3, with a high of $15.00 and a low of $11.00. This average price target has increased by 27.88% over the past month.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm

TRMR

Tremor Intl (NASDAQ:TRMR) has received 2 bullish and 4 somewhat bullish ratings from analysts in the last quarter. The average 12-month price target for the stock is $12.83, a 1.31% decrease from the previous average of $13.00.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm

DBRG

Over the past 3 months, 6 analysts have published their opinion on DigitalBridge Gr (NYSE:DBRG) stock. The company has an average price target of $18.83, with a high of $25.00 and a low of $12.50. The average price target has increased by 19.18% over the past month.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm

ANSS

Ansys's (NYSE:ANSS) short percent of float has risen 5.34% since its last report, with 936 thousand shares sold short, which is 1.38% of all regular shares available for trading. This increase in short interest can act as an indicator of market sentiment towards a particular stock. Ansys's peer group average for short interest as a percentage of float is 3.17%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm

DEO

Diageo's (NYSE:DEO) short percent of float has fallen 15.38% since its last report, with 1.22 million shares sold short, which is 0.22% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards Diageo. Compared to its peers, Diageo has less short interest as a percentage of float, with an average of 4.29%.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm

MDNA

Over the past 3 months, 4 analysts have published their opinion on Medicenna Therapeutics (NASDAQ:MDNA) stock. The average price target is $2.62, implying an upside from the current price of $0.3831. This represents a 67.25% decrease from the previous average price target of $8.00.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 7:00 pm